Unlike animals, plants do not possess an adaptive immune system with antibodies or T cells to fight viral infections. Instead ...

AIRNA, a transatlantic RNA editing biotech, is prepping to launch its lead asset into clinical trials with fuel from a $155 ...

Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a ...

Before a prostate biopsy is performed, various preliminary screening procedures are typically conducted. These include a ...

RNA-based therapeutics are gaining traction due to advancements in delivery technologies, despite historical challenges with ...

AIRNA’s lead candidate AIR-001 works by correcting the most common pathologic mutation driving the rare disease alpha-1 ...

Fungal infections are on the rise globally. According to a study by the Manchester Fungal Infection Group, in 2022, ...

Aqemia announces it is broadening and accelerating its computational platform to target RNAs using its physics-enabled ...

New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

While AI offers remarkable efficiency, the pharmaceutical industry must address concerns about “black box” predictions – AI ...

There is an urgent need for precision immunotherapy strategies that simultaneously target both tumor cells and immune cells ...

Korro Bio's OPERA platform offers precise RNA editing for genetic diseases like Alpha-1 antitrypsin deficiency. Learn more on ...